ArticleFrontiers in pharmacology2026
Comparison of conbercept and ranibizumab for the treatment of idiopathic choroidal neovascularization using optical coherence tomography angiography and multifocal electroretinography.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to compare the efficacies of conbercept and ranibizumab for the treatment of idiopathic choroidal neovascularization (ICNV) using optical coherence tomography angiography (OCTA) and multifocal electroretinography (mfERG). Methods: Sixty patients with ICNV were retrospectively assessed and followed up in this retrospective comparative cohort study. Thirty patients were assigned to the conbercept group, and 30 patients were assigned to the ranibizumab group. Patients in both groups were treated with 1+ pro re nata. Best-corrected visual acuity (BCVA), macular central retinal thickness (CRT), and CNV blood flow area before treatment and at 1, 3, 6, and 12 months after treatment were obtained. The first positive peak (P1) amplitude density in ring 1 and intraocular pressure (IOP) were recorded at baseline and the last follow-up. Results: The follow-up duration was 12 months. BCVA (logMAR) improved at 1, 3, 6, and 12 months after the injection, and the CRT and CNV blood flow area significantly decreased in both groups relative to their values before treatment (p < 0.05). The P1 amplitude densities in ring 1 at baseline were 50.97 ± 8.05 nv/deg Conclusion: Compared with intravitreal ranibizumab, intravitreal conbercept had a similar therapeutic effect in improving the structure and function on ICNV but with fewer injections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.